Circulating immune complexes in advanced Hodgkin's disease: Qualitative analysis and prognostic significance

Archivum Immunologiae et Therapiae Experimentalis

Volumn 48, Issue 3, 2000, Pages 195-200

  Tomasević, Zoran ^a,b   Jelić, Svetislav ^a,b  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^b Institut za radiologiju   (Serbia)

Author keywords

Hodgkin's disease; Immune complexes; Prognostic factors

Indexed keywords

ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; CHLORMETHINE; MOPP PROTOCOL; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ADULT; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BLOOD; DISEASE FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; PRECIPITATION; PROGNOSIS;

ADULT; ANTIGEN-ANTIBODY COMPLEX; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; C-REACTIVE PROTEIN; DISEASE-FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MECHLORETHAMINE; MIDDLE AGED; PRECIPITATION; PREDNISONE; PROCARBAZINE; PROGNOSIS; VINCRISTINE;

EID: 0033643064     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. AMLOT P. L., PUSSEL B., SLANEY J. M. and WILLIAMS B. D. (1978): Correlation between immune complexes and prognostic factors in Hodgkin's disease. Clin. Exp. Immunol., 31, 166-175.
2. AMLOT P. L., SLANEY J. M. and WILLIAMS B. D. (1976): Circulating immune complexes and symptoms in Hodgkin's disease. Lancet, 1, 449-451.
3. AZIZ M., DASS T. K. and RATTAN A. (1992): Role of circulating immune complexes as prognostic indicators of lympho-reticular and mesenchymal malignancies in children. J. Trop. Pediatr., 38, 185-188.
4. BROWN C. A., LONG J. C., CAREY K. and WEITZMAN S. A. (1978): Circulating immune complexes in Hodgkin's disease. Am. J. Med., 64, 289-294.
5. BRUSAMOLINO E., ORLANDO E., MORRA E., CASTELLI G., PAGNUCCO G., LIVRAGHI A., ASTORI C., SANTAGOSTINO A., LAZZARINO M. and BERNASCONI C. (1994): Analysis of long-term results and prognostic factors among 138 patients with advanced Hodgkin's disease treated with the alternating MOPP/ABVD chemotherapy. Ann. Oncol., 5, 53-57.
6. CHAPMAN A. L. N. and RICKINSON A. B. (1998): Epstein-Barr virus in Hodgkin's disease. Ann. Oncol., 9, 5-16.
7. DE VITA V. T., SERPICK A. and CARBONE P. (1970): Combination chemotherapy in the treatment of advanced Hodgkin's discase. Ann. Intern. Med., 73, 891-895.
8. GRUSS H. J., BRACH M. A., DREXLER H. G., BROSS K. J. and HERRMANN F. (1992): Interleukin 9 is expressed by primary and cultured Hodgkin and Reed-Sternberg cells. Cancer Res., 52, 1026-1031.
9. INMAN R. D. and DAY N. K. (1981): Immunologic and clinical aspects of immuno complex disease. Am. J. Med., 70, 1097-1106.
10. JUCKER M., ABTS H., LI W., SCHINELLER R., MERZ H., GUNTHER A., VON KALLE C., SCHAADT M., DIAMANTSTEIN T. and FELLER A. C. (1991): Expression of interleukin-6 and interleukin-6 receptor in Hodgkin's disease. Blood, 77, 2413-2418.
11. LAMBERT P. H., DIXON F. J. and ZUBLER R. H. (1978): A WHO collaborative study for the evaluation of eighteen methods for detecting immune complexes in serum. J. Clin. Lab. Immunol., 1, 1-15.
12. LOEFFLER M., MAUCH P. and MACLENNAN K. (1992): Review on prognostic factors. Ann. Oncol., 3, 63-66.
13. OSMOND A. P., GEWURTZ H. and FRIEDENSON B. (1977): Partial amino-acid sequences of human and rabit C-reactive proteins: Homology with immunoglobulins and histocompatibility antigens. Proc. Natl. Acad. Sci. USA, 74, 1214-1218.
14. OUCHTERLONY C. (1958): Double diffusion in gel technique. Progt. Alerg., 5, 1-78.
15. POPPEMA S., POTTERS M., VISSER L. and VAN DER BERG M. (1998): Immune escape mechanism in Hodgkin's disease. Ann. Oncol., 9, 21-24.
16. RALPH C. and WILLIAMS M. D. (1981): Immune complexes: A clinical perspective. Am. J. Med., 71, 743-745.
17. RIHA I., HASKOVA V., KASLIK J., MAIEROVA M. and STRANSKY J. (1979): The use of polyethylenglycol for immune complex detection in human sera. Mol. Immunol., 16, 489-493.
18. ROSENBERG S. A. (1994): The treatment of Hodgkin's disease. Ann. Oncol., 5, 17-21.
19. STRAUSS D., GAJNOR J. J. and MYERS J. (1990): Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. J. Clin. Oncol., 8, 1173-1179.
20. VLOCK D. R. (1990): Immune complexes and malignancy. Immunol. Ser., 53, 555-566.
21. WALKER L., HAY F. C. and ROITT I. M. (1979): Characteristics of complexes for arming and inhibiting effector cells for antibody-dependent cell-mediated cytotoxicity. Clin. Exp. Immunol., 36, 397-407.
22. WIEDERKEHR F., BUELER M. R. and VONDERSHMITT D. J. (1991): Chromatographic and elektrophoretic studies of circulating immune complexes in plasma. J. Chromatogr., 566, 77-87.